This is achieved through the direct binding of p62 to NLR proteins of the inflammasome, further underscoring the potential of p62 as a therapeutic target in managing the severity of Legionnaires’ disease (Ohtsuka et al., 2014). Here, SQSTM1 is linked to Legionnaires' disease.